阿德里安蒂奇：当颜值足够时。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-11-08 DOI:10.1016/j.medj.2024.10.004

Alfredo Addeo, Stephen V Liu

引用次数: 0

摘要

ADRIATIC1研究标志着局限期小细胞肺癌（LS-SCLC）治疗取得了重大进展，研究显示化疗后使用durvalumab进行巩固治疗可显著提高总生存期（OS）和无进展生存期（PFS）。这将durvalumab确立为治疗LS-SCLC的新标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ADRIATIC: When face value is enough.

The ADRIATIC¹ study marks a major advancement in limited-stage small cell lung cancer (LS-SCLC), showing that consolidation therapy with durvalumab after chemoradiation significantly improves overall survival (OS) and progression-free survival (PFS). This establishes durvalumab as the new standard of care for LS-SCLC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.